John Rhea Barton Professor and Chair, Department of Surgery, Perelman School of Medicine, University of Pennsylvania
General Surgery
Dr. Jeffrey A. Drebin, MD
|
|
Give Review
Jeffrey Drebin is an expert in the field of General Surgery. He studied medicine at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He over the years received 7 awards: "America's Top Doctors", "Philadelphia Magazine", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Super Doctor", "Fellow (FACS)" and "Top MD". Jeffrey Drebin has written publications. He has 81 publications published with PubMed. The lastest paper is: 'Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.' He is registered with Medicare.
Publications
- Efficacy of adjuvant chemotherapy for small bowel adenoCarcinoma: A propensity score-matched analysis.
- Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
- The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy.
- The efficacy of adjuvant therapy for pancreatic invasive intraDuctal papillary mucinous neoplasm (IPMN).
- Minimally invasive gastrectomy for gastric adenoCarcinoma in the United States: Utilization and short-term oncologic outcomes.
- Drain Management after Pancreatoduodenectomy: Reappraisal of a Prospective Randomized Trial Using Risk Stratification.
- Analysis of cyst size and tumor markers in the management of Pancreatic cysts: support for the original Sendai criteria.
- Adjuvant Radiation Therapy Treatment Time Impacts Overall Survival in Gastric Cancer.
- Targeted transgastric drainage of isolated pancreatic Duct segments to cure persistent pancreaticocutaneous fistulas from pancreatitis.
- Quantifying the Burden of Complications Following Total Pancreatectomy Using the Postoperative Morbidity Index: A Multi-Institutional Perspective.
- Establishing a Quantitative Benchmark for Morbidity in Pancreatoduodenectomy Using ACS-NSQIP, the Accordion Severity Grading System, and the Postoperative Morbidity In...
- Prophylactic octreotide for pancreatoduodenectomy: more harm than good?
- Defining the post-operative morbidity index for distal pancreatectomy.
- Implications of inadequate lymph node staging in resectable gastric Cancer: A contemporary analysis using the National Cancer Data Base.
- Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database.
- Surgical Palliation for Pancreatic Malignancy: Practice Patterns and Predictors of Morbidity and Mortality.
- Detection of Circulating Pancreas Epithelial Cells in Patients with Pancreatic Cystic Lesions.
- A Randomized Prospective Multicenter Trial of Pancreaticoduodenectomy With and Without Routine Intraperitoneal Drainage.
- A Multi-Institutional External Validation of the Fistula Risk Score for Pancreatoduodenectomy.
- Assessing the impact of a fistula after a Pancreaticoduodenectomy using the Post-operative Morbidity Index.
- Extrahepatic cholangioCarcinoma developing in the setting of AIDS cholangiopathy.
- A contemporary analysis of survival for resected pancreatic Ductal adenocarcinoma.
- Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic Cancer.
- Incidence of venous thromboEmbolism in patients undergoing surgical treatment for malignancy by type of neoplasm: An analysis of ACS-NSQIP data from 2005 to 2010.
- Timing of preoperative pharmacoprophylaxis for pancreatic surgery patients: a venous thromboembolism reDuction initiative.
- Pancreatic cystic neoplasms: why not operate?
- Targeted suppression of beta-catenin blocks Intestinal adenoma formation in APC Min mice.
- Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenoCarcinoma: a single-institution phase II study.
- Trastuzumab in breast Cancer.
- Suppression of beta-catenin by antisense oligomers augments tumor response to isolated limb perfusion in a rodent model of adenomatous polyposis coli-mutant colon Cancer.
- Five-year survival after resection of hepatic metastases from colorectal Cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-...
- Down-regulation of beta catenin inhibits the growth of esophageal Carcinoma cells.
- Radical antegrade modular pancreatosplenectomy.
- Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenoCarcinoma.
- Use of a bipolar vessel-sealing device for parenchymal transection during Liver surgery.
- Prospective trial of a blood supply-based technique of Pancreaticojejunostomy: effect on anastomotic failure in the Whipple procedure.
- Utility of staging laparoscopy in subsets of peripancreatic and Biliary malignancies.
- Risk factors for aggressive nonfunctional pancreatic Neuroendocrine tumors and the role of endoscopic ultrasound guided fine-needle aspiration.
- Risk of malignancy in resected cystic Tumors of the pancreas < or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report.
- Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation.
- Evolution and current status of the Whipple procedure: an update for gastroenterologists.
- Molecular cloning and chromosomal localization of the human homologue of a B-lymphocyte specific protein tyrosine kinase (blk).
- Prevention of breast tumour development in vivo by downregulation of the p185neu receptor.
- Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene.
- Differential antigen presentation in tumor immunity.
- The role of antigen-presenting cells in regulating the immune response to tumor antigens.
- Regulation of the immune response to tumor antigens. X. Activation of third-order suppressor T cells that abrogate anti-tumor immune responses.
- Suppressor T cells and the immune response to Tumors.
- Genetically restricted antigen presentation for immunological tolerance and suppression.
- Identification of an I-J+ antigen-presenting cell required for third order suppressor cell activation.
- Inhibition of tumor growth by monoclonal anti-I-J antibodies.
- Analysis of hapten-specific T suppressor factors: genetic restriction of TsF1 activity analyzed with synthetic hybrid suppressor molecules.
- Regulation of the immune response to tumor antigens. IX. In vitro Lyt-1+2- cell proliferative responses to cellbound or subcellular tumor antigen.
- The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.
- Development of monoclonal antibodies reactive with the proDuct of the neu oncogene.
- Purification of mouse monoclonal antibodies from ascitic fluid by DEAE Affi-Gel Blue chromatography.
- Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.
- Stage- and tissue-specific expression of the neu oncogene in rat development.
- Monoclonal antibodies specific for the neu oncogene proDuct directly mediate anti-tumor effects in vivo.
- Down-modulation of an oncogene protein proDuct and reversion of the transformed phenotype by monoclonal antibodies.
- Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.
- Biological effects of monoclonal antireceptor antibodies reactive with neu oncogene proDuct, p185neu.
- Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon Carcinoma xenografts.
- Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon Cancer cells.
- Results of a new strategy for reconstruction of Biliary injuries having an isolated right-sided component.
- Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal Carcinoma: a prospective database study.
- HER2/neu antisense targeting of human breast Carcinoma.
- The "hidden cystic Duct" syndrome and the infundibular technique of laparoscopic cholecystectomy--the danger of the false infundibulum.
- Pancreaticoduodenectomy for lymphoepithelial cyst of the pancreas.
- Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human Disease.
- Down-regulation of HER2/neu expression induces apoptosis in human Cancer cells that overexpress HER2/neu.
- Management of diagnostic dilemmas of the pancreas by ultrasonographically guided laparoscopic biopsy.
- Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies.
- Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents.
- Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast Carcinoma cells that overexpress HER2/neu.
- A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or Biliary tract carcinoma.
- Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.
- Prevention of surgical resident attrition by a novel selection strategy.
- ErbB receptors: from oncogenes to targeted Cancer therapies.
- The role of HER2 in early breast Cancer metastasis and the origins of resistance to HER2-targeted therapies.
Schools
Harvard Medical School
Johns Hopkins Hospital
Procedures Preformed
- Appendectomy, Open
- Arteriovenous Shunt Creation
- Cholecystoenterostomy
- Colectomy
- View All
Conditions Treated
- Abdominal Pain
- Atelectasis
- Bile Duct Cancer
- Biliary Atresia
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
Awards
- America's Top Doctors
- Philadelphia Magazine
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
- Fellow (FACS)
- Top MD
Education
-
Johns Hopkins University -
Harvard Medical School
Hospital
-
Hospital of the University of Pennsylvania -
Pennsylvania Hospital -
Penn Presbyterian Medical Center -
Philadelphia Veterans Affairs Medical Center
Drug Facts
| NPI NUMBER | 1629005905 | |
| NPPES Provider LastName | DREBIN | |
| NPPES Provider FirstName | JEFFREY | |
| NPPES Provider ZIPCode | 191045127 | |
| NPPES Provider State | PA | |
| Specialty Description | General Surgery | |
| Total Claim Count | 55.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629005905 |
| Last Name Of The Provider | DREBIN |
| First Name Of The Provider | JEFFREY |
| View All |
Similar Doctors
|
|
Dr. Paul D. Rodrigue, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie G. Grossman, MD |
|
|
Dr. Sarah E. Koller, MD |
|
|
Dr. Lois V. Stefanowicz, DO |
|
|
Dr. Farhan Khan, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Seiji Yamaguchi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rohit S. Soans, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jay E. Dujon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katerina Dukleska, MD |
|
|
Dr. Meera Gupta, MD |
|
|
Dr. Rudolf N. Staroscik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judy D. Ross, MD |
|
|
Dr. Michael L. Nance, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul G. Curcillo II, MD
This Doctor is OpenDoctor Recommended.
|